Directors of the Center for Genetic Engineering and Biotechnology (CIGB) of Cuba and the National Center for Medical Research in Endocrinology of Russia signed an agreement on Tuesday in Moscow to expand scientific-medical ties.
The signing ceremony took place at the centenary Moscow Institute of Endocrinological Diseases, where the director of the institution, Natalia Mokrysheva, described the event as an important step in strengthening Russian-Cuban ties in joint work within the field of endocrinology.
“We are confident that our cooperation will open new horizons for the implementation of innovative treatment methods and scientific research, which, in turn, will benefit our patients and the entire medical community,” said the member of the Russian Academy of Science. “We remain confident that the integration agreement with the CIGB will open new opportunities to expand and deepen scientific cooperation, facilitate the exchange of experiences and clinical training, friendly and business relations in the field of medicine and health care,” Mokrysheva added.
In statements to Prensa Latina, the deputy general director of the CIGB, Jorge Valdés, said he was pleased that both centers had consolidated their long-standing friendship with the signing of this agreement. “I hope that our cooperation will be very fruitful, both scientifically and practically,” he said.
He explained that the project will expand the development of molecular genetic research for the treatment of hereditary, genetic and endocrine diseases, while combining the capabilities of both institutions to continue advancing molecular genetic research for the benefit of Russian and Cuban patients.
“The step we are taking today is the result of joint work carried out over the last 10 years, through the exchange of different therapies of Cuban origin such as the treatment to combat diabetic foot ulcers with the use of the drug Heberprot-P,” said Valdés.
From 2017 to 2019, the Diabetic Foot Department of the National Medical Research Center of Endocrinology of Russia conducted clinical trials with Heberprot-P, which demonstrated its pronounced efficacy in the treatment of chronic wounds of the lower limb in people with diabetes, according to the research of the Russian entity. Studies have shown that the drug, created by specialists from the CIGB, significantly reduces wound healing time, hospital stay and disability in this category of patients.
Based on the test results, this method was registered in the clinical guidelines for the treatment of diabetic foot ulcers within the Russian health care system. On February 18, 1925, the National Medical Research Center of Endocrinology was founded, attached to the Ministry of Health of the Russian Federation, as a unique and modern medical, diagnostic, scientific research and educational complex of endocrinological profile for the Slavic nation and the countries of the Commonwealth of Independent States.
Source: www.cubadebate.cu
Views: 0
